Replies to post #3881 on Long Term Investment, Biotech & High Yield Dividen

[peewee]

Morning ax ! :-)

[califax]

HGSI -

added to LONGTIME-portfolio @ 1,19€

did additional dd...
IMO (could become a MONSTER)



http://www.hgsi.com/

Three Products in Late-Stage Development
We now have three promising products in late-stage development, moving toward commercialization. We have reported the positive results of two Phase 3 trials of Albuferon®, and we plan to file global marketing applications in fall 2009. Two Phase 3 trials are ongoing for LymphoStat-B® in patients with lupus, with results expected in July and November 2009. We are developing both of these products in collaboration with world leaders in the pharmaceutical industry. Also in late-stage development is ABthrax™, which offers a new way to address the threat of inhalation anthrax and is being developed under a contract with the U.S. Government.

High-Potential Pipeline
Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by our TRAIL receptor antibodies for cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.

---------------------------------------------------------------

http://www.hgsi.com/products.html

CLINICAL DEVELOPMENT PIPELINE

HGS has a well balanced and deep portfolio of novel drugs directed toward diseases that represent significant unmet medical need. Three of these products are in late-stage development.

In March 2009 and December 2008, we reported positive Phase 3 results from our Phase 3 trials of Albuferon® (albinterferon alfa-2b) in patients with chronic hepatitis C. Filings of global marketing applications are planned in fall 2009. Two Phase 3 trials are ongoing for LymphoStat-B® (belimumab) in patients with systemic lupus erythematosus (SLE), with results expected in July and November 2009. ABthrax™ (raxibacumab) is in late-stage development for the treatment of inhalation anthrax.

Right behind these late-stage products is an emerging high-potential mid-stage pipeline, led by our anti-cancer products, HGS-ETR1 (mapatumumab) and HGS 1029, an IAP inhibitor – both for the treatment of cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.

---------------------------------------------------------------

Q4/2008 QUARTERLY RESULT
http://www.hgsi.com/quarterly-results/human-genome-sciences-announces-fourth-quarter-and-full-year-2008-financial-results-and-key-develop.html